Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD - da Silva, B S; Cupertino, R B; Rovaris, D L; Schuch, J B; Kappel, D B; Müller, D; Bandeira, C E; Victor, M M; Karam, R G; Mota, N R; Rohde, L A; Contini, V; et al. (Molecular psychiatry, 2018)
Keywords: 38/77; 631/208; 692/53/2423; Adult; Analysis; Attention Deficit and Disruptive Behavior Disorders - complications; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention Deficit Disorder with Hyperactivity - genetics; Attention deficit hyperactivity disorder; Behavioral Sciences; Biological Psychology; Blood proteins; Care and treatment; Central Nervous System Stimulants; Childhood mental disorders; Dosage and administration; Exocytosis; Exocytosis - genetics; Exocytosis - physiology; Female; Genes; Genetic aspects; Genetic polymorphisms; Genetic research; Humans; Hyperactivity; Male; Medicine; Medicine & Public Health; Messenger RNA; Methylphenidate; Methylphenidate - pharmacology; Methylphenidate - therapeutic use; mRNA; Neurosciences; Oppositional defiant disorder; original-article; Outcome Assessment (Health Care); Pharmacodynamics; Pharmacogenetics; Pharmacogenomics; Pharmacotherapy; Polymorphism, Genetic; Practice guidelines (Medicine); Psychiatry; RNA; Short term; SNAP receptors; Stimulants; Synaptotagmin; Synaptotagmin I - genetics; Synaptotagmin I - metabolism; Syntaxin 1 - genetics; Syntaxin 1 - metabolism; Treatment Outcome; Vesicle-Associated Membrane Protein 2 - genetics; Vesicle-Associated Membrane Protein 2 - metabolism